Audit: QRS - Mescaline for Health & Longevity
Audit conducted on 05/08/2026 04:15 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 81 |
| Failed | 0 |
| N/A | 10 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked across every populated variable: dose 300–500 mg (ER l.427), sulfate ~25% less potent (l.433/473), morning 08:00–10:00 (l.435), two attendants / 12 h / 30 h follow-up (l.427), 11–14 h duration (l.435), 6.4–14 h dose range (l.289), all 10 biomarker rows and targets (l.510–519), cadence (l.521). No unsupported statement found. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Lasting benefit remains plausible but unproven” mirrors the ER Conclusion (“a plausible but unproven lasting benefit”, l.563); the ER’s “⚠️ Conflicted” markers are carried through as “(conflicted)”. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Thresholds and severity classes are carried at ER strength (≥160/100 mmHg, MI within six months, NYHA III/IV, QTc >500 ms, eGFR <30, Child-Pugh B/C, age <18 / <25 with family history). |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come from the ER’s absolute contraindications and the “Populations who should avoid this intervention entirely” bullet; cautions come from the ER’s “— caution” bullets. No Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, citations, author names, NCT identifiers, or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are present. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted register matching the ER (e.g. “plausible but unproven”, “(conflicted)”). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven throughout, with concrete dose, timing, and target values that make the intervention actionable. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents thresholds and observed values without instructing the reader. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No prescriptive or advisory constructions in the QRS’s own voice; the only clinician-referral wording is the fixed template disclaimer. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “should”, “recommend”, “advise”, or equivalent in any populated variable. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are glossed or standard (e.g. “Corrected QT interval (QTc)”, “Estimated glomerular filtration rate (eGFR)”, “High-sensitivity C-reactive protein (hs-CRP)”). |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every list item is a bare noun phrase; monitoring “Why” cells are single clauses. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no “you”/”your” in the document. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a reader who will screen, monitor vitals, and run a full baseline laboratory panel. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Protocol assumes a supervised 12-hour session with two attendants, a recovery day, echocardiography, and a 10-marker baseline panel. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | The burden presented (two clear days, trained attendants, electrocardiogram, washouts) is explicitly not general-population oriented. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Benefits are tiered with the ER’s evidence grades and the “(conflicted)” flags retained; the risk card leads with the acute physiological cost. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The term “anti-aging” does not appear; the header uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal clinical register throughout (“myocardial infarction”, “adverse”, “hallucinogen persisting perception disorder”); no consumer-grade substitutes. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified in place: “Protocol” (l.445), “Time to effect” (l.482), “Benefits” (l.524), “Risk & Side Effects” (l.621), “Monitoring” (l.655), “Qualitative Assessment” (l.791), “Contraindications” (l.556), “Key Interactions” (l.587), tier labels High/Medium/Low/Speculative, and the Marker/Target/Why headers (l.659–661). |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | Structural diff against [qrs_template] confirms every template span is present: page_title, header_topic, header_subline_date, header_subline_model, at_a_glance, action_1–3 (label/value/sub), time_1–3 (label/value/sub), benefits_, stop_items, caution_items, risks_, marker_1–10 (name/target/why), monitoring_cadence, qualitative_item_1–7. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The non-audited spans website="evidence_review", website="audit", and website="full_review" are byte-identical to the template, as is all CSS and page structure. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section relevant to the QRS is empty; every source section (Protocol, Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Monitoring Protocol & Defining Success) carries content, so no empty-state phrasing applies. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Monitoring row labels are taken verbatim from the ER biomarker table (l.510–519); the protocol and time cells carry aspect labels as required by 10.2/11.1 rather than ER bullet labels. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Marker names match the ER table wording; tier and section headings are the fixed template strings. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters anywhere in the file (verified by Unicode range scan); the ER’s 🟩/🟥/🟨 tier markers and ⚠️ flags are not carried through. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed to the template’s per-section budget rather than expanded: single-clause list items, no mechanistic rationale, no effect sizes, and no explanatory prose beyond the sub-lines the template provides. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after <!doctype html> on line 1, and precedes the template comment at line 16 and <html> at line 17. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at line 3 and closing “—” at line 13; the comment-opening text on line 2 precedes it. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment and not duplicated by any rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration: "00:05" is quoted, which is required because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | er_filename: mescaline_2026-0805-0002_Opus_ER.md (l.4), matching the source ER. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | qrs_prompt_version: 26.7.02 (l.5), matching the version badge of QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | qrs_creation_date: 2026-0805-0346 (l.6), correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | qrs_creator_ai_nickname: Opus (l.7). |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | qrs_creator_ai_fullname: Opus 5 (l.8). |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number, no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | qrs_filename: mescaline_2026-0805-0002_Opus_QRS.html (l.9), matching the file itself. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: no stray whitespace or unnecessary quoting on any of the nine frontmatter values. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | The title reads “Mescaline for Health & Longevity - Quick Reference Sheet” (l.22), matching canonical_topic with the ampersand entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | header_topic is “Mescaline for Health & Longevity” (l.417). |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | header_subline_date is 08/05/2026 (l.421), the MM/DD/YYYY form of qrs_creation_date 2026-0805. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | header_subline_model is “Opus 5” (l.425), matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header carries only the title and the template subline; no badge, version stamp, alternate-names line, or audit date. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses the ER Conclusion (l.559–563) into what the compound does, what controlled studies established, and what remains unproven. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 55 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Cactus source and serotonin mechanism (l.559), full-day duration (l.559), dose-related mood lift / nausea and vomiting / blood-pressure rise (l.559), plausible-but-unproven lasting benefit (l.563). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “peyote and San Pedro cacti”, “serotonin receptors”, “blood pressure”; no acronyms, receptor subtypes, or drug-class labels. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No study names, years, sample sizes, or p-values; refers generically to “Controlled studies in healthy people”. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No odds ratios, confidence intervals, percentages, or effect sizes. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 14 items trace to the ER Key Interactions & Contraindications section (l.377, 381, 393, 399). |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Complete coverage: MAO inhibitors, lithium, and harmala preparations from the absolute-contraindication bullets, plus all 11 population exclusions from l.399. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | All 14 items are individual <li> elements inside the [stop_items] span (l.559–583). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every item is a bare fact; no dashes introducing trailing clauses, no mechanism, no citations. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Preserved: “≥160/100 mmHg repeated”, “within six months”, “New York Heart Association Class III or IV”, “above 500 ms”, “below 30 mL/min/1.73 m²”, “Child-Pugh Class B or C”, “under 25 with a family history of psychosis”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication bullets; thresholds are written out (e.g. “≥160/100 mmHg”, “above 500 ms”). |
| 8.7 | If no [stop_items] are present the section is left empty | N/A | [stop_items] are present (14 items), so the section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All 11 items trace to the ER “— caution” bullets at l.379, 383, 385, 387, 389, 391, 393, 395, 397. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Correctly split: harmala-containing botanicals and lithium are placed in Contraindications, while the serotonin precursors and St John’s wort from the same ER bullet appear here. No item is duplicated across the two gates. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | All 11 items are individual <li> elements inside the [caution_items] span (l.590–612). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every item is a bare drug class or exposure; no mechanism, consequence, or mitigation text carried over. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved and trimmed: “(fluoxetine, sertraline, venlafaxine)”, “(amitriptyline, nortriptyline, clomipramine)”, “(risperidone, olanzapine, quetiapine, ketanserin)”, “(amphetamine, methylphenidate, pseudoephedrine)”, “(diphenhydramine, doxylamine)”, “(5-hydroxytryptophan, L-Tryptophan, St John’s wort)”, “(caffeine, yohimbine, synephrine, ephedra)”. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its interaction bullets; parenthetical content is limited to example drug names. |
| 9.7 | If no [caution_items] are present the section is left empty | N/A | [caution_items] are present (11 items), so the section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from the ER Therapeutic Protocol section (l.427, 433, 435). |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing, and setting are the three decision-critical implementation aspects of the Basel reference protocol. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable implementation aspects are present in the ER Therapeutic Protocol section, so all three action sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action variables carry substantive ER-derived content; no placeholders remain. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Peak subjective effect, durable psychological benefit, and full effect duration — the three timing facts the ER quantifies (l.482, 289, 435). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered High-tier benefit first (acute mood elevation → peak subjective effect), then the Medium-tier durable psychological benefit, then total duration. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects are present in the ER, so all three time sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time variables carry substantive ER-derived content, including the 6.4 h–14 h dose-duration range. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER provides time-to-effect information (Practical Considerations → “Time to effect”, plus the duration data in Mechanism of Action and Therapeutic Protocol), so the section is retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items map one-to-one onto ER Expected Benefits headings (l.169–233). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four tier spans are populated: benefits_high (l.526), benefits_medium (l.531), benefits_low (l.537), benefits_speculative (l.544). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER benefit headings reduced to noun phrases; no magnitudes, mechanisms, or study details carried over. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No effect sizes, sample notes, mechanistic hints, or example studies appear in parentheses; the only parenthetical is the “(conflicted)” evidence flag replacing the ER’s “⚠️ Conflicted” heading marker, which 4.4 bars from being rendered as an emoji. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four benefit tiers (High, Medium, Low, Speculative) contain items in the ER, so no span needs to be hidden. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items map one-to-one onto ER Potential Risks & Side Effects headings (l.267–349). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four tier spans are populated: risks_high (l.623), risks_medium (l.630), risks_low (l.636), risks_speculative (l.643). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Items are the ER risk headings reduced to noun phrases; no frequencies, mechanisms, or study details carried over. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content at all in the risks card; the ER’s incidence figures and severity grades are omitted as required. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four risk tiers (High, Medium, Low, Speculative) contain items in the ER, so no span needs to be hidden. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All rows derive from the ER Monitoring Protocol & Defining Success biomarker table (l.508–519). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 10 ER biomarkers are present with matching targets: seated blood pressure, resting heart rate, QTc, eGFR, ALT, potassium/red-cell magnesium, complete blood count, fasting glucose and insulin, hs-CRP, and echocardiogram valve morphology. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | [monitoring_cadence] (l.785) condenses the ER cadence paragraph at l.521: vitals every 30–60 minutes across the acute window, 24-hour check, 1- and 4-week reviews, 6–12 month panel, echocardiography above a few sessions per year. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All seven items derive from the ER qualitative-marker list at l.525–531. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | Complete: sleep quality, mood stability, alcohol and tobacco consumption, cognitive clarity, persisting visual phenomena, subjective well-being, and anxiety/avoidance after a challenging experience. |
Issues 05/08/2026 04:15
Pass rate 100.00%. No issues found.
Issues 05/08/2026 04:06
- 1.1 — Time-to-effect label not in ER:
time_1_label(line 488) reads “Peak mood elevation” for the 2–4 hour window, but ER line 482 states only “peak subjective effect between two and four hours”; the mood-specific label is a synthesis not present in the source. - 12.3 — Openness added to High benefit:
benefits_high(lines 528–529) appends “, and openness to experience” to the ER heading “Dose-Dependent Elevation of Positive Mood and Well-Being”, which is an elaboration and duplicates the Low-tier entry “increases in trait openness and personality change”.
Fixes 05/08/2026 04:06
- 1.1 — Time-to-effect label not in ER: Changed
time_1_labelfrom “Peak mood elevation” to “Peak subjective effect”, the wording used in the ER for the 2–4 hour window. - 12.3 — Openness added to High benefit: Trimmed
benefits_highto “Dose-dependent elevation of positive mood and well-being”, removing “, and openness to experience”, which duplicated the Low-tier trait-openness entry.
Issues 05/08/2026 03:55
- 4.5 — Content exceeds one A4 page: The sheet renders to roughly 2.3 A4 pages at the template’s print metrics; the least-condensed regions are the Monitoring table (lines 687–835, which carries the ER’s full “Why Measure It?” sentences across 10 rows), the two decision gates (lines 577–634, 25 items with complete drug lists), the protocol and time-to-effect
subcells (lines 455–535), and the Qualitative Assessment items (lines 854–894), which retain the ER’s trailing explanatory clauses.
Fixes 05/08/2026 03:55
- 4.5 — Monitoring rationales compressed: Rewrote all ten
marker_#_whycells from the ER’s full sentences into fragments (e.g. “Mescaline raises blood pressure for the full 8–14 hour duration” → “Raised for the full 8–14 hour duration”), cutting roughly a quarter of the table’s rendered height while keeping the ER’s reasoning and all marker names and target ranges unabbreviated. - 4.5 — Contraindication gate trimmed: Shortened the 14 stop items by trimming the longest example-drug lists and dropping redundant wording (“within the previous six months” → “within six months”, “Heart failure (New York Heart Association Class III or IV)” → “Heart failure, New York Heart Association Class III or IV”); every ER contraindication and its threshold, staging, and time-window qualifiers are retained.
- 4.5 — Key Interactions gate trimmed: Reduced the named-drug parentheticals per class (e.g. stimulants/decongestants/beta-agonists from seven examples to three) and tightened item stems, keeping all 11 ER interaction classes and at least one named example each.
- 4.5 — Protocol and time-to-effect subs condensed: Shortened the six
subcells (e.g. dose sub now “Hydrochloride, single oral dose; six doses of 100–800 mg characterised. Sulfate roughly 25% less potent by weight”), removing one to two rendered lines per cell. - 4.5 — Monitoring cadence condensed: Reduced the cadence paragraph from the ER’s verbatim 340-character sentence to a 250-character version covering the same six checkpoints.
- 4.5 — Qualitative items stripped of rationale clauses: Removed the trailing “since…/which is the window in which…” explanatory tails from all seven items, taking each to a single rendered line.
- 4.5 — Low-tier risk list tightened: Shortened
risks_lowfrom 236 to 186 characters by dropping redundant modifiers (“and recurrent perceptual symptoms”, “acute”, “other”), retaining all four ER risk headings.